166 related articles for article (PubMed ID: 22169459)
1. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Miyata H; Yano M; Yasuda T; Hamano R; Yamasaki M; Hou E; Motoori M; Shiraishi O; Tanaka K; Mori M; Doki Y
Clin Nutr; 2012 Jun; 31(3):330-6. PubMed ID: 22169459
[TBL] [Abstract][Full Text] [Related]
2. Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Miyata H; Yano M; Yasuda T; Yamasaki M; Murakami K; Makino T; Nishiki K; Sugimura K; Motoori M; Shiraishi O; Mori M; Doki Y
Nutrition; 2017 Jan; 33():204-210. PubMed ID: 27644137
[TBL] [Abstract][Full Text] [Related]
3. Relationship between immunological parameters and the severity of neutropenia and effect of enteral nutrition on immune status during neoadjuvant chemotherapy on patients with advanced esophageal cancer.
Motoori M; Yano M; Yasuda T; Miyata H; Peng YF; Yamasaki M; Shiraishi O; Tanaka K; Ishikawa O; Shiozaki H; Doki Y
Oncology; 2012; 83(2):91-100. PubMed ID: 22777298
[TBL] [Abstract][Full Text] [Related]
4. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Miyata H; Sugimura K; Motoori M; Fujiwara Y; Omori T; Yanagimoto Y; Ohue M; Yasui M; Miyoshi N; Tomokuni A; Akita H; Kobayashi S; Takahashi H; Yano M
Anticancer Res; 2017 Jun; 37(6):3053-3059. PubMed ID: 28551644
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
[TBL] [Abstract][Full Text] [Related]
6. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.
Shimakawa T; Naritaka Y; Asaka S; Isohata N; Murayama M; Konno S; Yoshimatsu K; Shiozawa S; Katsube T; Ogawa K
Anticancer Res; 2008; 28(4C):2321-6. PubMed ID: 18751413
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of combined chemotherapy with nedaplatin, adriamycin, and 5-FU (NAF), and clinical factors affecting its effect in patients with advanced esophageal cancer].
Hasegawa H; Fujitani K; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2591-5. PubMed ID: 22189224
[TBL] [Abstract][Full Text] [Related]
9. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA
Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
[TBL] [Abstract][Full Text] [Related]
14. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
16. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Voelter V; Schuhmacher C; Busch R; Peschel C; Siewert JR; Lordick F
Ann Thorac Surg; 2004 Sep; 78(3):1037-41. PubMed ID: 15337044
[TBL] [Abstract][Full Text] [Related]
17. Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer.
Dähn D; Martell J; Vorwerk H; Hess CF; Becker H; Jung K; Hilgers R; Wolff HA; Hermann RM; Christiansen H
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):44-52. PubMed ID: 19679407
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer.
Uno T; Isobe K; Kawakami H; Ueno N; Kobayashi H; Shimada H; Mastubara H; Okazumi S; Nabeya Y; Shiratori T; Ochiai T; Kawata T; Ito H
Anticancer Res; 2004; 24(4):2483-6. PubMed ID: 15330202
[TBL] [Abstract][Full Text] [Related]
20. Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.
Matsumoto A; Nishikawa K; Yuda M; Tanaka Y; Tanishima Y; Arakawa Y; Ishibashi Y; Sakuyama T; Omura N; Mitsumori N; Aiba K; Yanaga K
Anticancer Res; 2016 Apr; 36(4):1937-42. PubMed ID: 27069183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
